Aprea Therapeutics Inc
NASDAQ:APRE
Aprea Therapeutics Inc
NASDAQ:APRE
Price:
5.3242 USD
-0.48%
Market Closed
Updated:
May 6, 2024
Aprea Therapeutics Inc
Cash from Financing Activities
|
Aprea Therapeutics Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Aprea Therapeutics Inc
NASDAQ:APRE
|
Cash from Financing Activities
$5.1m
|
CAGR 3-Years
225%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Aprea Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
5.1m
USD
5.1m
USD
Based on the financial report for Dec 31, 2023, Aprea Therapeutics Inc's Cash from Financing Activities amounts to 5.1m USD.
What is Aprea Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-38%
-38%
Over the last year, the Cash from Financing Activities growth was 656%. The average annual Cash from Financing Activities growth rates for Aprea Therapeutics Inc have been 225% over the past three years , -38% over the past five years .
You don't have any saved screeners yet
